RBR-7m4v7b招募中2 期
A phase II randomized, double-blind, placebo controlled study of the safety and efficacy of ranitidine in diabetic patients with severe sepsis and septic shock.
Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo0 个研究点开始时间: 2018年7月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 —（—）
入选标准
- •Patient with age greater than 18 years; Admitted to the Emergency Unit of Clinical Hospital of Ribeirão Preto medical school of University of São Paulo (UE-HCFMRP/USP); diagnosis of diabetes mellitus or serum glucose > 200 mg / dL at the admission; diagnosis of severe sepsis or septic shock; ability of the patient or his or her legal representative to decide whether or not to participate in the survey before completing 48 hours of admission.
排除标准
- •Septic Patients who do not have the criteria for severe sepsis or septic shock; continuous use of ranitidine or other H2 antagonist; hypersensitivity to ranitidine or other H2 blockers; pregnant women; participation in another study; diagnosis of HIV; realization of chemotherapy in the last 30 days; palliative care; lymphoproliferative disease; refusal to signing the consent form (CF) or not to participate in the study; need of procedure or examination with contrast which requires the use of ranitidine as premedication.
研究者
相似试验
进行中（未招募）
1 期
Safety and efficacy and tolerability of M1095 in subjects with moderate to severe, chronic plaque-type psoriasisModerate to severe chronic plaque-type psoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2017-004611-38-CZBond Avillion 2 Development LP300
进行中（未招募）
1 期
A phase 2b randomized, double-blind, placebo controlled, multi-center 12-week study with an additional 40-week follow-up assessment of efficacy, safety and tolerability of M1095 in subjects with moderate to severe chronic plaque-type psoriasisEUCTR2017-004611-38-HUBond Avillion 2 Development LP383
进行中（未招募）
1 期
Safety and efficacy and tolerability of M1095 in subjects with moderate to severe, chronic plaque-type psoriasisEUCTR2017-004611-38-BGBond Avillion 2 Development LP300
进行中（未招募）
不适用
Comparison of three doses of tiotropium inhalation solution delivered via a device called Respimat® inhaler with the aim to evaluate the efficacy and the safety of tiotropium. Patients with moderate persistent asthma will receive each treatment for 4 weeks once daily: 1.25, 2.5, 5.0 microgram tiotropium and placebo. The sequence of the 4 treatments will be randomly assigned to the patients, and neither the patient nor the treating investigator knows when the patient gets which treatment.moderate persistent asthmaMedDRA version: 14.0Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-018471-26-DEBoehringer Ingelheim Pharma GmbH & Co. KG120
进行中（未招募）
不适用
A Phase II randomised, double-blind, placebo controlled, cross-over efficacy and safety comparison of three doses of tiotropium inhalation solution delivered via Respimat® inhaler (1.25, 2.5 and 5.0 µg once daily) versus placebo in patients with moderate persistent asthma. - TinA dose confirmation in GINA 3/4moderate persistent asthmaMedDRA version: 13.1Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-018471-26-ATBoehringer Ingelheim RCV GmbH & Co KG120